Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8N3T1
UPID:
GLT15_HUMAN
Alternative names:
Polypeptide GalNAc transferase-like protein 2; Polypeptide N-acetylgalactosaminyltransferase-like protein 2; Protein-UDP acetylgalactosaminyltransferase-like protein 2; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-like protein 2
Alternative UPACC:
Q8N3T1; A6NMN1; B2R638; F1LIP6; Q86T60; Q96C46; Q96DJ5
Background:
Polypeptide N-acetylgalactosaminyltransferase 15 (GALNT15) plays a crucial role in the biosynthesis of O-linked oligosaccharides by transferring N-acetyl-D-galactosamine to serine or threonine residues on proteins. Despite its weaker activity compared to GALNT2, GALNT15 can add multiple GalNAc residues to the Muc5AC peptide, indicating its ability to work alongside other GALNT proteins and showing a preference for Muc1a as a substrate.
Therapeutic significance:
Understanding the role of Polypeptide N-acetylgalactosaminyltransferase 15 could open doors to potential therapeutic strategies.